Evidence map›Paper›PMID 32577059›Full record

ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2020

Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.

Senad Bajramovic, Jasmin Alic, Edna Skopljak, Adisa Chikha, Sanela Vesnic, Velda Smajilbegovic, Damir Aganovic

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Senad BajramovicUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Jasmin AlicUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Edna SkopljakMedical Faculty, University Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.
Adisa ChikhaInstitute of Pathology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Sanela VesnicInsitute of Radiology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Velda SmajilbegovicOncology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Damir AganovicUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
University of Sarajevo · BASarajevo School of Science and Technology · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-muscle-invasive bladder cancer (NMIBC) is usually effectively treated with transurethral resection (TUR), most often followed by intravesical instillation of bacillus Calmette-Guérin (BCG) or intravesical chemotherapy. Although the precise mechanism of BCG immunotherapy is still unclear, a local immune response is presumed. However, a number of severe side effects and complications are related to intravesical immunotherapy.

aimAim of this report is to present rare case of the renal granulomatous disease in a patient previously treated with intravesical instillation of BCG immunotherapy, following TURBT. In addition, we performed review of previously reported cases of renal granulomas following intravesical BCG immunotherapy. CASE REPORT: A 79-year-old man was presented to Urology Clinic due to clinically verified tumor of the urinary bladder. After transurethral resection of bladder tumor, histopathological analysis revealed the diagnosis of papillary urothelial high-grade pT1 carcinoma. Intravesical BCG immunotherapy was initiated, according to protocol currently used in our institution. Upon completion of therapy with BCG, we re-examined the patient and, using ultrasound, found a change in the right kidney, resembling moth bites not seen on CT scan before TURBT. Additionally, CT-guided core-needle biopsy of the affected kidney was performed, and the specimen was sent for histopathological analysis, which revealed chronic necrotizing granulomatous inflammation. Antituberculotic therapy was initiated for 6 months. Upon completion of antituberculotic therapy, control CT-scan was performed at follow-up, indicating regression of changes on the right kidney.

conclusionThis case report emphasizes the importance of consistent implementation of follow-up protocol and the identification of lesions during the asymptomatic period and enables the proper treatment of the disease. To reduce the incidence of adverse effects of BCG treatment for bladder tumors, an individualized approach is needed.

Indexed as

CystoscopyAdministration, IntravesicalAgedAntitubercular AgentsBCG VaccineBiopsy, Large-Core NeedleCarcinoma, Transitional CellHumansImmunologic FactorsMaleTomography, X-Ray ComputedTuberculosis, RenalUrinary Bladder NeoplasmsAntitubercular AgentsBCG VaccineImmunologic FactorsBCGbladder cancerimmunotherapyrenal tuberculosis

Identifiers

PMID32577059
PMCPMC7296402
OpenAlexW3022578697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.